L3VLUP
ProSign in

PEN · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

PENVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • PEN
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterPENVRTX
Q3 202013 holders, $2.3bn31 holders, $21.9bn
Q4 202010 holders, $2.5bn30 holders, $18.4bn
Q1 202114 holders, $3.6bn31 holders, $15.4bn
Q2 202112 holders, $3.3bn30 holders, $12.7bn
Q3 202113 holders, $3.3bn35 holders, $10.1bn
Q4 202113 holders, $3.5bn28 holders, $12.4bn
Q1 20229 holders, $2.5bn23 holders, $16.1bn
Q2 20229 holders, $1.3bn25 holders, $18.1bn
Q3 202211 holders, $2.0bn22 holders, $18.4bn
Q4 202213 holders, $2.6bn28 holders, $18.4bn
Q1 20239 holders, $3.5bn26 holders, $21.4bn
Q2 202319 holders, $4.2bn27 holders, $24.7bn
Q3 202314 holders, $2.8bn33 holders, $24.3bn
Q4 202311 holders, $3.3bn32 holders, $28.6bn
Q1 202411 holders, $2.6bn31 holders, $29.8bn
Q2 202410 holders, $2.0bn29 holders, $33.4bn
Q3 202410 holders, $2.0bn27 holders, $33.5bn
Q4 202411 holders, $2.4bn26 holders, $28.5bn
Q1 202514 holders, $2.9bn21 holders, $35.4bn
Q2 202515 holders, $2.7bn21 holders, $32.3bn
Q3 202510 holders, $2.9bn22 holders, $25.9bn
Q4 202516 holders, $3.8bn26 holders, $31.8bn
Q1 202620 holders, $2.1bn25 holders, $31.8bn
Q2 202617 holders, $2.2bn26 holders, $34.6bn
PEN

Penumbra Inc

Holders
11
Reported value
$3.3bn
Buyers
6
Sellers
5

Breadth +1 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
32
Reported value
$28.6bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only PEN (3)

Baillie Gifford & Co, ExodusPoint Capital Management LP, Soros Fund Management LLC

Only VRTX (24)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Brevan Howard Capital Management LP, Caxton Associates LLP, D. E. Shaw & Co., Farallon Capital Management LLC, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →